Pharma
Sartorius shares suffer double-digit decline – Uncertainty in demand weighs down
Sartorius shares came under significant pressure again on Wednesday as investors reacted with concern to recent developments.
The shares of the biotech supplier Sartorius slid towards their lowest price since April 2020 on Wednesday, with a double-digit percentage loss. On the XETRA exchange, they fell by 13.41 percent to 211.20 euros, making them the weakest performer in the DAX. Shares of the subsidiary Sartorius Stedim Biotech similarly lost value on Euronext, ultimately dropping 13.76 percent to 152.95 euros.
The losses of Sartorius also dragged down the shares of the diagnostics company QIAGEN, which are listed on the DAX, falling by 5.62 percent to 38.80 euros.
Sartorius participated in a healthcare conference by Citigroup in London this Wednesday. There have been no official announcements from Sartorius so far. However, it was reported from the trading floor that Sartorius might have expressed continued caution regarding equipment demand, which unsettled market participants.
The uncertainty regarding the demand for biotech equipment is apparently undermining investors' confidence and has led to significant share price losses.
